Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41375-020-0891-0 http://scihub22266oqcxt.onion/10.1038/s41375-020-0891-0 32518419!7282206!32518419     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Leukemia 2020 ; 34 (7): 1805-1815 Nephropedia Template TP {{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation |pdf=|usr=}}{{32518419}} gab.com Text The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation JO: Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=32518419 #FOAvip A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th(,) 2020, 14 patients with a CIS >/= 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by >/=25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958). Twit Text FOAVip The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation ????Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=32518419 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32518419 #FOAvip English Wikipedia <ref>{{Cite pmid|32518419}}</ref> The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation #MMPMID32518419 La Rosee F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosee P Leukemia 2020[Jul]; 34 (7): 1805-1815 PMID32518419show ga A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th(,) 2020, 14 patients with a CIS >/= 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by >/=25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958). |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Betacoronavirus/drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy/enzymology/immunology/virology[MESH] |Cytokine Release Syndrome/*drug therapy/enzymology/immunology/virology[MESH] |Cytokines/antagonists & inhibitors/genetics/immunology[MESH] |Drug Administration Schedule[MESH] |Female[MESH] |Gene Expression Regulation[MESH] |Humans[MESH] |Immunity, Innate/drug effects[MESH] |Inflammation[MESH] |Janus Kinase 1/*antagonists & inhibitors/genetics/immunology[MESH] |Janus Kinase 2/*antagonists & inhibitors/genetics/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Nitriles[MESH] |Pandemics[MESH] |Patient Safety[MESH] |Pneumonia, Viral/*drug therapy/enzymology/immunology/virology[MESH] |Protein Kinase Inhibitors/*therapeutic use[MESH] |Pyrazoles/*therapeutic use[MESH] |Pyrimidines[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/*drug therapy/enzymology/immunology/virology[MESH] |T-Lymphocytes/drug effects/immunology/virology[MESH]The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe sys(epmc).pdf DeepDyve Pubget Overpricing